# OnCo record nct06690840 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06690840/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06690840", "NCT06690840" ;
  schema:name "Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients"@en ;
  schema:alternateName "AZALEA"@en ;
  schema:description "A phase 2 trial of atezolizumab, cyclophosphamide and vinorelbine in triple-negative breast cancer, run by European Institute of Oncology, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06690840/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06690840> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "tnbc-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vinorelbine/> .